A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

Active:	Yes
Cancer Type:	Unknown Primary	NCT ID:	NCT07419295
Trial Phases:	Phase III	Protocol IDs:	2870-031 (primary) NCI-2026-01873 2024-520014-22-00 jRCT2051260020 MK-2870-031 U1111-1316-4390
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Merck Sharp and Dohme LLC
NCI Full Details:	http://clinicaltrials.gov/show/NCT07419295

Summary

Researchers are looking for new ways to treat locally advanced or metastatic urothelial
cancer (UC). Current treatments for locally advanced or metastatic UC include
chemotherapy, immunotherapy, and targeted therapy.

Researchers want to know if giving sacituzumab tirumotecan (sac-TMT), the trial medicine,
can treat locally advanced or metastatic UC that got worse after certain treatments. The
goal of this trial is to learn if people who receive sac-TMT live longer than those who
receive certain non-platinum chemotherapies.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.